Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes. Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.

How Did Telma Become a 1000+ Cr Brand?

The untold story of Glenmark's phenomenal success in building...

Astra Zeneca Tops Indian Pharma in New Introductions 2024

Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Tariffs and Indian Generics: Is Trump Cutting His Nose to Spite His Face?

Trump’s Tariffs Threaten US Drug Affordability The Value of...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Marketing

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Policies/Sales

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Strategy

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Manish Bajaj

Manish Bajaj is presently, Cluster Head - India Business at Dr Reddy's. During his tenure of 10 years at Dr. Reddy’s, he has handled multiple roles including Strategy, Strategic Marketing, Sales Force Excellence, Sales Training, Portfolio Management, Innovation, Medical Affairs, and Regulatory Affairs.

Crafting a Digital Strategy: The Roadmap for 2021

Featured Manish Bajaj - December 16, 2020

In many situations, technology upgradation is often construed as digital transformation. In a recently conducted survey by Altimeter, 88% of companies said that they were undergoing ‘digital transformation’ but only 25% said that they did so with the purpose beyond investing in new technology. The real definition of digital transformation is the realignment of, or new investment in technology, business models, and processes to create value for customers in a dynamic digital economy.